New hope for cervical cancer patients who Can't take chemo

NCT ID NCT07450963

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase II trial tests a drug called cadonilimab combined with radiation therapy for women with advanced cervical cancer who cannot receive standard chemotherapy due to age or health issues. The study will enroll 45 participants and measure how many have a complete response (no cancer detected) after treatment. The goal is to see if this combination can improve outcomes compared to radiation alone.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

Cadonilimab (a drug that helps the immune system fight cancer)

What this could lead to

If successful, this could offer a new treatment option for cervical cancer patients who cannot receive standard chemotherapy, potentially improving tumor shrinkage and long-term control.

What could go wrong

This is a small, early-phase trial (45 people) with no control group. The combination may not work better than radiotherapy alone, and side effects from the immune drug could be serious.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LOCALLY ADVANCED CERVICAL CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cervical cancer cervical carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.